The global emphysema treatment market is being aided by the growth of the overall chronic obstructive pulmonary disease treatment market. The global chronic obstructive pulmonary disease treatment market is expected to grow at a CAGR of 4.8% in the forecast period of 2022-2027.
The key players of the global emphysema treatment market are Pulmonx Corporation, Kamada Limited, Pfizer Inc., and Uptake Medical Technology Inc., among others.
Emphysema, a type of chronic obstructive pulmonary disease (COPD), is a lung condition that damages the alveoli(air sacs) in the lungs, which results in shortness of breath. The rise in the number of tobacco smokers worldwide has been the driving factor for the growth of the emphysema treatment industry. The increase in the number of people affected with chronic lung disorders and the availability of advanced diagnostic facilities have increased the demand for treatment for emphysema. Meanwhile, factors such as the sedentary lifestyle, growing urbanisation, and industrialisation are further boosting the industry’s growth. The global market is expected to enjoy steady growth in the forecast period with an increase in research and development activities and advancements in the medical sector.
Region-wise, North America leads the global emphysema treatment market, followed by Europe. As for the Asian-pacific region, the increase in the number of the smoking population and increasing pollution levels is expected to propel the market growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
|Headquarters:||California, United States|
Pulmonx Corporation, one of the leading players in the industry, is a commercial medical technology company. The company focuses on supplying planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System, and StratX Lung Analysis Platform. The solutions offer a minimally invasive treatment option for patients with severe emphysema. The company also offers a non-surgical opportunity for bronchoscopic lung volume reduction.
Kamada Ltd., another leading player in the industry, is a biopharmaceutical company specialising in the manufacture and marketing of proteins as pharmaceutical products. The company is responsible for producing approximately ten injectable and marketable drugs used in over 15 countries. The company has been able to feature in the 500 fastest growing companies in Europe list according to the Deloitte index back in 2012.
|Headquarters:||New York City, United States|
Pfizer Inc., a global pharmaceutical and biotechnology corporation, is involved in developing vaccines and medicines, such as Viagra, Zoloft, and Lipitor. The company also started its research on the COVID-19 vaccine back in March 2020, when the COVID-19 pandemic had become apparent. Pfizer partnered with BioNTech to get a conclusive result for the COVID-19 vaccine situation. The vaccine has been shown the green flag in various countries, including the United States, the United Kingdom, and Canada. The company applies science and global resources to deliver innovative therapies that extend and significantly improve lives.
|Headquarters:||Seattle, United States|
Uptake Medical Technology Inc. is a medical device company dedicated to treating patients suffering from a pulmonary disease with vapor ablation. Bronchoscopic Thermal Vapor Ablation is a surgical free, implant free therapy developed for lung diseases, such as emphysema and lung cancer. Vapor ablation is simply applying pure steam to tissue. The procedure for performing this treatment is simple, quick, and non-invasive, taking less than fifteen minutes.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.